Chronic Lymphocytic Leukemia Clinical Trial
Official title:
Open Label Multicenter Study of Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
With conventional treatments (i.e. iv Ig, steroids) the overall response rate of ITP
secondary to LPD is generally lower than in primary ITP, and usually not higher than 50% (95%
CI 27-72). Eltrombopag which has proved very effective in primary ITP could be effective also
in ITP secondary to LPDs.
This novel ITP specific treatment might spare these patients not only from bleeding risk but
also from toxic or inappropriate cytotoxic therapies, not otherwise demanded by the burden of
the underlying disease.
The denomination of Chronic Lymphoproliferative Disorders (LPD) encompasses a variety of
indolent lymphomas grouped into a single clinical category and, as such, this terminology is
not included in the current WHO classification. With indolent lymphomas clinicians refer to
those lymphomas not associated with an aggressive clinical course and in which often
treatment can be delayed. Specifically the following lymphomas by the WHO classification will
be considered among indolent lymphomas: small lymphocytic lymphoma/chronic lymphocytic
leukemia, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma,
lymphoplasmacytic lymphoma, hairy-cell leukemia, Hodgkin's lymphoma. In 1 to 5% of the
different LPDs (lowest in follicular lymphoma, highest in chronic lymphocytic leukemia) a
clinically relevant thrombocytopenia, often complicated by bleeding symptoms, may complicate
the clinical course, frequently still when the tumor burden is low and not demanding
treatment. This thrombocytopenia, when not accompanied by massive bone marrow tumor
infiltration or not secondary to chemotherapeutic treatment, is thought to share an immune
pathogenic mechanism similar to primary immune thrombocytopenia (ITP).
With conventional treatments (i.e. iv Ig, steroids) the overall response rate of ITP
secondary to LPD is generally lower than in primary ITP, and usually not higher than 50% (95%
CI 27-72). Therefore, any new treatment having a response rate above 50% but not inferior
than 20% could be considered a promising treatment for ITP secondary to LPD. Furthermore, no
significant platelet increase is expected without treatment in ITP secondary to LPD.
Eltrombopag which has proved very effective in primary ITP could be effective also in ITP
secondary to LPDs.
This novel ITP specific treatment might spare these patients not only from bleeding risk but
also from toxic or inappropriate cytotoxic therapies, not otherwise demanded by the burden of
the underlying disease.
Phase 2, single arm, open-label, prospective, multicenter, safety/efficacy study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Active, not recruiting |
NCT04240704 -
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
|
Phase 1 | |
Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03280160 -
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
|
Phase 2 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT05417165 -
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT04028531 -
Understanding Chronic Lymphocytic Leukemia
|
||
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Recruiting |
NCT04679012 -
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
|
Phase 2 | |
Recruiting |
NCT05405309 -
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05023980 -
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|